ALAMEDA, Calif., Feb. 22 /PRNewswire-FirstCall/ -- Xenogen Corporation
(Nasdaq: XGEN), maker of advanced imaging systems including instruments,
biological solutions and software designed to accelerate drug discovery and
development, today announced that it will release 2005 fourth quarter and
full-year financial results after the close of market on Thursday, March 2,
2006. Xenogen's management will host a conference call at 5:00 p.m. Eastern
Time (2:00 p.m. Pacific Time).
What:
Xenogen will release 2005 fourth quarter and full-year results, followed
by a teleconference.
When:
Teleconference begins on Thursday, March 2nd at 5:00 p.m. Eastern Time
(2:00 p.m. Pacific Time).
Who:
David Carter, Chief Executive Officer and Chairman; Dr. Pamela Contag,
President; William Albright, Chief Financial Officer.
How:
Dial 800-946-0706 (domestic) or 719-457-2638 (international) to listen to
the call. A live webcast also will be made available at http://www.xenogen.com.
A phone replay will be available for 48 hours following the completion of
the call by dialing 888-203-1112 (domestic) or 719-457-0820 (international),
and entering in reservation code 5244395. The webcast will be archived and
available on the Xenogen website for 14 days.
About Xenogen Corporation
Xenogen Corporation is a leading biotechnology company offering an
integrated suite of biophotonic real-time in vivo imaging and genetic
modification technologies that can help expedite drug discovery and
development, and significantly reduce the cost and time to market for new
therapies. Xenogen's VivoVision(TM) Systems non-invasively illuminate and
monitor biological processes within living mammals, at the molecular level, in
real time. The technology provides higher quality in vivo data earlier in the
drug discovery and development process. VivoVision(TM) Solutions improve
discovery and pre-clinical research in multiple therapeutic areas.
VivoVision(TM) Biosciences represents more than 15 years of experience in the
creation and characterization of animal models, including genetic
modifications, comprehensive phenotyping, compound profiling and custom design
and production of light producing cells, microorganisms and animals.
More information is available at http://www.xenogen.com.
NOTE: Xenogen(R), Living Image(R), VivoVision(TM) and IVIS(R) are
trademarks of Xenogen Corporation.
SOURCE Xenogen Corporation
 back to top
Related links:
http://www.xenogen.com
CONTACT:
William A. Albright, Chief Financial Officer
of Xenogen Corporation, +1-510-291-6104; or investors, Jordan
Goldstein of Financial Dynamics, +1-415-439-4500, for Xenogen
Corporation; or media, Kelly O'Brien of Manning Selvage & Lee,
+1-415-364-3840, for Xenogen Corporation
|
